Compare · LLY vs PCRX
LLY vs PCRX
Side-by-side comparison of Eli Lilly and Company (LLY) and Pacira BioSciences Inc. (PCRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PCRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 1101.9x PCRX ($1.01B).
- Over the past year, LLY is up 52.7% and PCRX is up 18.6% - LLY leads by 34.1 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 4 for PCRX).
- Both have 25 recent analyst ratings on file.
- Company
- Eli Lilly and Company
- Pacira BioSciences Inc.
- Price
- $1178.57+0.73%
- $25.59+0.02%
- Market cap
- $1.11T
- $1.01B
- 1M return
- +5.00%
- +12.23%
- 1Y return
- +52.71%
- +18.61%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2011
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Pacira BioSciences Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
Latest PCRX
- Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
- Pacira BioSciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
- Director Hirawat Samit was granted 6,405 shares (SEC Form 4)
- Senior Vice President, Finance Riker Lauren sold $143,702 worth of shares (6,115 units at $23.50) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 62,284 units (SEC Form 4)
- SEC Form 4 filed by Director Wiggans Thomas G
- Director Christie Christopher was granted 6,405 shares, increasing direct ownership by 38% to 23,059 units (SEC Form 4)
- Director Young Alethia was granted 6,405 shares, increasing direct ownership by 56% to 17,798 units (SEC Form 4)
- Director Yang Michael J. was granted 6,405 shares, increasing direct ownership by 48% to 19,798 units (SEC Form 4)